{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021275","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.445906+00:00","generated_at":"2026-06-15T04:57:43.232760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track","bullets":["Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.","R&D expenses $12.0M (up from $5.6M); G&A expenses $4.1M (up from $2.1M).","Cash, cash equivalents and investments totaled $88.5M at March 31, 2023.","Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease.","Expects to complete Phase 2 enrollment mid-2023; top-line data ~9 months after enrollment completion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021275","json":"https://secwatch.observer/filing/0000950170-23-021275.json","markdown":"https://secwatch.observer/filing/0000950170-23-021275.md","text":"https://secwatch.observer/filing/0000950170-23-021275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/0000950170-23-021275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/antx-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:57:43.232760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e005850e0a5f4ef06e6255bd08eb5b44943825f3","claim":"AN2 Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $15.3 million.","evidence_excerpt":"Net loss was $15.3 million for the three months ended March 31, 2023, compared to $7.7 million in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/0000950170-23-021275-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$15.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}